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Abstract
OBJECTIVE—To assess change in overactive bladder (OAB) symptoms up to 5-years after 
surgery and to identify associated predictors of change from baseline.
METHODS—This is a secondary analysis of data from three multicenter urinary incontinence 
surgical trials of women with stress predominant mixed urinary incontinence assigned to Burch 
colposuspension, autologous fascial sling, retropubic or transobturator midurethral slings. The 
primary outcome was improvement of ≥70% from baseline in symptoms measured by the Urinary 
Distress Inventory–Irritative (UDI-I) subscale. Surgical groups were compared within respective 
trials. Generalized linear models were fit using 1-year and up to 5-year data.
RESULTS—Significant improvements in UDI-I scores were reported by each surgical group one 
year after surgery (p<0.001). Most women (50–71%) reported improvement in OAB symptoms. 
Improvements were similar between midurethral sling groups at 1-year (65.5% vs 70.7%, p=0.32) 
(OR=0.83 [95% CI 0.57–1.20] for retropubic vs. transobturator sling) and throughout the 5-year 
follow-up period. More women reported OAB symptom improvement after Burch compared to 
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pubovaginal sling (67.9% vs 56.6%, p=0.01) (OR=1.59 [95% CI 1.10–2.31] for Burch vs. sling); 
this group difference at 1-year persisted throughout the 5-year follow-up. At 1-year, 50.0–64.3% 
of patients reported ≥70% improvement in urgency incontinence. This proportion declined to 
36.5–54.1% at 5-years (p<0.001). Preoperative use of anticholinergics and urodynamic parameters 
were not predictive of OAB symptom change after surgery.
CONCLUSIONS—Most women with stress predominant mixed urinary incontinence 
experienced significant improvement in OAB symptoms after incontinence surgery although this 
initial improvement diminished over time. Obesity blunted symptom improvement.
Introduction
Stress urinary incontinence (SUI) surgery has high success rates, levels of satisfaction and 
durability (1–5). The urgency component of mixed urinary incontinence is considered a risk 
factor for treatment failure and reduced satisfaction (4, 6–9). The effect of surgery on 
bladder storage symptoms of the overactive bladder (OAB) syndrome (10) namely urinary 
urgency, frequency and nocturia with or without urgency urinary incontinence is poorly 
understood. In a multicenter study comparing Burch and autologous fascial slings, nearly all 
(92%) women with mixed incontinence expected their co-existent urgency, frequency and 
nocturia would also improve after their SUI surgery despite counseling efforts to the 
contrary (11). Thus, persistence of any storage symptoms, not just urgency incontinence, can 
deleteriously affect a patient’s perception of surgical success and satisfaction.
OAB symptoms after surgery have been variably characterized as improved, persistent, 
exacerbated and new in onset (12–15). Most studies indicate that symptom improvement 
diminished over time. Studies reporting predictors of improvement have targeted baseline 
urodynamic study (UDS) parameters (12). With fewer UDS being done, identifying clinical 
parameters associated with change in OAB symptoms would help inform pre-operative 
counseling.
The databases of Urinary Incontinence Treatment Network (UITN) are the largest pool of 
longer-term outcomes from over 1800 well-characterized women who underwent surgery 
for stress-predominant mixed incontinence. We previously published on post-surgical 
change in the urgency incontinence component of mixed incontinence. The primary 
objective of this secondary analysis is to assess how anti-incontinence procedures 
comprehensively affect all OAB symptoms from 1 to 5 years postoperatively and to identify 
predictors of this symptom change.
Materials and Methods
This is a secondary analysis of previously unreported data from three UITN multicenter 
trials exploring the potential effects of procedures on symptoms of the OAB syndrome. The 
methods, population demographics and outcomes have been published (16–18). Eligibility 
criteria consistent across the three studies included predominant SUI defined as all of the 
following: self-reported SUI symptoms of >3 months duration, predominance of SUI 
symptoms on the Medical, Epidemiologic and Social Aspects of Aging (MESA) 
questionnaire and demonstrable leakage on provocative stress test (19). None of the studies 
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required discontinuation of OAB medications. The Stress Incontinence Surgical Treatment 
Efficacy Trial (SISTEr) and its extended follow-up study followed women up to 5-years 
after randomization to the Burch colposuspension or autologous pubovaginal sling (17, 1). 
The Trial Of MidUrethral Slings (TOMUS) and its extended follow-up study queried 
women up to 5-years after randomization to retropubic or transobturator midurethral sling 
(18,19). Our analyses also included 1-year outcome data from women who underwent either 
a retropubic or transobturator midurethral sling procedure in the Value of Urodynamic 
Evaluations (ValUE) trial (14). IRB approval was maintained at clinical sites and the 
coordinating center and all patients provided written consent.
OAB symptoms were prospectively ascertained with two validated measures: the Irritative 
subscale of the Urogenital Distress Inventory (UDI-I) (20) and the urge symptom index of 
the Medical, Epidemiologic, and Social Aspects of Aging (MESA) questionnaire (20). The 
UDI-I (score range 0–100) queries the presence and bother associated with symptoms of 
frequency, urgency, urgency incontinence, nocturia, bedwetting and large volume leakage. 
Bother is recorded on a 4-point Likert scale (1= not at all to 4= greatly). The UDI-I was the 
primary outcome measure for the analyses in this study. The urge component of the MESA 
questionnaire queries how urine loss is experienced with 6 urge items including loss of urine 
preceded by an urge to urinate, or uncontrollable voiding with little or no warning, triggered 
by washing hands, cold weather or drinking cold beverages. Responses range from never, 
rarely, sometimes to often (score range 0–18). For this analysis, the MESA Urge score was 
transcribed to an Index which was expressed as a percentage of the total possible urge score 
(0–100%).
Improvement in OAB syndrome was defined as a ≥70% decrease from baseline in UDI-I and 
the MESA Urge Index. This study-specific definition of clinically meaningful improvement 
in symptoms was based upon analyses from network data demonstrating that a 70% 
reduction in incontinence episodes was associated with the highest level of patient reported 
satisfaction (unpublished). Differences in procedure outcomes were only compared within 
each trial due to differences in trial eligibility criteria and allowable concomitant procedures. 
Analyses were performed on data from all patients with baseline and at least one post-
surgical time point including: at 1-year and annually up to 5-years after surgery. Time was 
treated as a continuous variable. Clinical, sociodemographic, procedure characteristics, 
urodynamic parameters and use of anticholinergic medications at baseline were assessed as 
potential predictors of change in bladder storage symptoms after surgery. They included age, 
race, parity, vaginal births, menopause and smoking status, BMI (25–<30, ≥30 kg/m2), POP-
Q stage, baseline UDI-I score, MESA Urge Index), and urodynamic parameters of detrusor 
overactivity, bladder volume at first desire, strong desire and maximum cystometric 
capacity.
Generalized estimating equations with a logit link function and compound symmetric 
covariance structure were used to test the treatment effect on OAB symptom improvement 
over time, adjusting for baseline UDI-I scores. To identify predictors of symptom 
improvement at 1-year, univariable logistic regression models were fit modeling the 
probability of improvement as a function of each covariate separately, adjusting for 
treatment group and baseline symptom scores. Odds ratios and 95% confidence intervals 
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described the associations between clinical parameters and OAB symptom improvement. 
The backward elimination method was used to select the final multivariable logistic 
regression models. Treatment group and baseline OAB symptom score were forced to 
remain in the model. Spearman correlation examined the association between 
“improvement” in bladder storage symptoms and satisfaction with surgery. Self-reported 
satisfaction was assessed with the question, “How satisfied or dissatisfied are you with the 
result of bladder surgery related to the following symptoms: “urine leakage”, “an urgency to 
urinate such that you fear not making it to the bathroom in time” and “frequent urination”?” 
with a 5-point Likert-type response range of: completely dissatisfied through completely 
satisfied. Using medication audits from each time point, we analyzed the effect of surgery 
type on change in OAB medication use over time. Statistical analyses were performed at the 
Data Coordinating Center (New England Research Institute, Watertown, MA) with SAS 
software, release 9.3 (SAS Institute Inc., Cary, NC). A 5% two-sided significance level was 
used.
RESULTS
Most patients in the 3 trials reported symptoms of the OAB syndrome. Table 1 indicates the 
proportion of patients reporting moderate to great bother on at least one symptom in the 
UDI-I. At baseline, the mean UDI-I scores and mean MESA Urge Index indicated moderate 
bladder storage symptoms. Each SUI procedure group reported significant post-operative 
improvement from baseline in UDI-I scores 1-year after surgery (p<0.001). Over time, the 
proportion of women reporting ≥70% improvement in OAB symptoms by UDI-I gradually 
declined for each surgical group (p<0.001), although about half to two-thirds of remaining 
study participants continued to report this level of symptom relief 5-years after their index 
surgery (Figure 1, Tables 2 and 3).
More women reported improvement in OAB symptoms on the UDI-I in the Burch group 
compared to the fascial sling group at 1-year (67.9% vs 56.6%, p=0.01), (OR=1.59 [95% CI 
1.10–2.31] for Burch vs. sling). This procedure advantage for the Burch persisted when 
analyses controlled for baseline symptom severity (UDI-I score) and was sustained through 
5-years (p=0.02). We found the significant symptom improvement in each midurethral sling 
group at 1-year was also sustained through 5-years in the TOMUS study (Table 3). 
Additionally, the proportion of women reporting symptom improvement did not differ 
between the routes of sling at 1-year in TOMUS, (OR=0.83 [95% CI 0.57–1.20]).
The proportion of patients achieving ≥70% improvement in incontinence on the MESA 
Urge Index at 1-year ranged from 50.0% to 64.3% (Tables 2,3 and 4). Again, this proportion 
declined over time in all groups to 36.5% – 54.1% at 5-years (p<0.001) (Tables 2 and 3, 
Figure 2). When surgical groups were compared within study, averaging the outcomes over 
all time points, we found no significant differences in the proportions who met our definition 
of improvement on the MESA Urge Index. Throughout the 5-year follow-up, the proportion 
of women reporting worsening of symptoms on the UDI-I ranged from 13.4–29.1% (Burch), 
19.8–30.2% (autologous sling) and 11.7–21.4% (transobturator midurethral sling) and 11.0–
21.3% (retropubic midurethral sling).
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A minority of patients reported preoperative and postoperative use of anticholinergic 
medication for OAB symptoms (7.2%–11.6% and 5.4%–11.3% respectively) (Table 5). We 
found that surgery type had no effect on use of OAB medication at any time points.
The satisfaction women reported with their surgery positively correlated with the magnitude 
of reduction in their OAB symptoms at all given time points, in all three trials. Patients with 
greater improvement in baseline OAB symptoms as measured by the UDI-I were more 
likely to express satisfaction with their surgery regarding overall urine leakage (p<0.001), 
their feeling of urgency (p<0.001) and their frequency of urination (p<0.001).
We identified few clinical parameters that were strongly associated with postoperative 
change in storage symptoms at 1-year. In the SISTEr trial, OAB symptom improvement on 
UDI-I was positively associated with hormone replacement therapy in menopausal women 
(adjusted OR 1.64 [95% CI 1.01–2.67]). Conversely, more vaginal births (OR 0.84, [95% CI 
0.75–0.95]) and BMI≥30 (compared to BMI 25–<30, OR 0.57,[95% CI 0.36–0.88]) reduced 
the likelihood of symptom improvement after SUI surgery.
Urodynamic data were analyzed from SISTEr (n=528), TOMUS (n=528) and ValUE 
(n=269) patients. Notably, we found no association in any trials between change in bladder 
storage symptoms and route of midurethral sling, increasing age, presence of pelvic organ 
prolapse, concomitant surgery, and urodynamic parameters of detrusor overactivity, bladder 
volume at first desire, strong desire or maximum cystometric capacity.
Discussion
The majority of women seeking surgery for SUI experience concomitant OAB symptoms. 
Reassuringly, this analysis found that 57–71% of women with stress predominant mixed 
incontinence can expect a ≥ 70% improvement in their co-existing urinary frequency, 
nocturia, urgency and urgency incontinence one year after surgery. Although the number of 
women reporting improvement declined over time, half to two thirds (46–65%) maintained 
this level of symptom improvement up to 5 years after surgery.
The extent of OAB symptom improvement was blunted by obesity and differed among the 
surgical groups indicating that presurgical counseling needs to be individualized and 
procedure specific. Interestingly, potentially relevant clinical factors such as age, smoking, 
preoperative use of anticholinergic medication and various urodynamic parameters were not 
predictors of postoperative improvement of the OAB syndrome.
The literature on the incidence of OAB symptoms after SUI surgery includes large series, 
RCTs, and reviews (3,8,12–15,21,22). We are limited in our ability to compare our findings 
to these studies because of differences in outcome measures, definitions of OAB symptoms 
and endpoints. Most studies, including our previously published outcomes of the SISTEr 
and TOMUS trials, have focused on post-surgical de novo urgency urinary incontinence and 
individual OAB symptoms. A few studies evaluated persistence or worsening of discrete 
OAB symptoms. In comparison, this analysis reports on change in all symptoms of the OAB 
syndrome.
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Post-surgical OAB symptom improvement and subsequent recurrence have been reported by 
others. Duckett et al reported that 29 of 46 (63%) women with idiopathic detrusor 
overactivity and stress incontinence experienced complete resolution of OAB symptoms 
after a TVT at a median follow-up of 12 (6–26) months. (22). Holmgren et al reported an 
60% cure rate of urgency and urgency incontinence up to 4 years after midurethral sling in 
1113 women with pre-operative mixed incontinence. This improvement declined to 40% at 
5 years and 30% at 4–8 years. They attributed the deterioration of their overall success rate 
to an increase in urgency urinary incontinence symptoms (23).
Obese women are 43% less likely to experience relief from their OAB symptoms compared 
to women who are overweight or normal weight. This is not surprising, given that obesity is 
an established risk factor for OAB syndrome and urinary incontinence (24,25). In a 5-year 
study of 1481 women, Handa found obesity to increase the odds of urinary urgency (odds 
ratio 2.89 [CI:2.00, 4.17]), urgency incontinence (odds ratio 2.63 [CI: 1.83, 3.78]), nocturia 
(odds ratio 1.67 [CI:1.21, 2.30]) and frequency (odds ratio 1.67 [CI:1.21, 2.30]).
In contrast to obesity, the urodynamic variables we evaluated were not predictive of change 
in OAB symptoms. Our analyses do not support their use in counselling women similar to 
our study population. Our finding differs from that of Kenton et al., who reported that 
detrusor overactivity at baseline in the SISTEr patients increased their odds of urgency 
urinary incontinence nearly 2-fold (OR 2.20, 95% CI 1.08–4.49, p=0.030). Their findings 
were specific to the Burch and autologous sling procedures which comprised less than half 
of our dataset. They were also limited to urgency urinary incontinence, one of four storage 
symptoms reflected in our analyses.
A strength of this analysis is its generalizability. The results reflect the long-term surgical 
outcomes of over 1600 well-characterized women with mixed incontinence after 4 different 
incontinence procedures. All storage symptoms of the OAB syndrome, not just urgency 
urinary incontinence, were quantified using validated, patient-reported measures 
preoperatively and annually for up to 5-years.
Several limitations are acknowledged. To report on a clinically meaningful improvement in 
OAB symptoms we created a non-validated definition of symptom improvement. This was 
justified by the absence of an established threshold of change in score on the UDI-I. We 
measured improvement in all OAB symptoms rather than the presence or absence of 
individual symptoms or the absolute change in the mean UDI-I scores. We felt this would be 
most useful in pre-operative counselling. None of the trials included a control group 
therefore we have not provided absolute evidence that SUI procedures reduce OAB 
symptoms. Lastly, a minority of our patients were taking anticholinergic medications before 
surgery. This may explain why none of the procedures influenced their use post-operatively 
and limits the generalizability of our findings in women who are using OAB medications 
pre-operatively. They may represent a population with more severe OAB symptoms or less 
tolerance.
Based upon our analyses, clinicians can counsel their patients planning a midurethral sling 
for stress predominant mixed incontinence that 65–71% can expect a significant 
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improvement in coexistent OAB symptoms. The symptom improvement does diminish over 
time and is less likely in obese patients.
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Figure 1. 
Percentage of participants who had ≥70% improvement from baseline in overactive bladder 
symptoms as measured on the Urogenital Distress Inventory-Irritative (UDI-I) subscale over 
time. Error bars indicate 95% confidence intervals. SISTEr (Stress Incontinence Surgical 
Treatment Efficacy trial) (A), TOMUS (Trial of Midurethral Slings) (B). RMUS, retropubic 
midurethral sling; TMUS, transobturator midurethral sling.
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Figure 2. 
Percentage of participants who had ≥70% improvement from baseline in urgency urinary 
incontinence as measured by the Medical, Epidemiologic, and Social Aspects of Aging 
questionnaire urge index over time. Error bars indicate 95% confidence intervals. SISTEr 
(Stress Incontinence Surgical Treatment Efficacy trial) (A), TOMUS (Trial of Midurethral 
Slings) (B). RMUS, retropubic midurethral sling; TMUS, transobturator midurethral sling.
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Table 5
Percentage of patients by trial group reporting use of anticholinergic medications at each time point.
Stress Incontinence Surgical Treatment Efficacy 
Trial1
Trial Of MidUrethral Slings2 Value of Urodynamic Evaluations 
Trial2
Baseline 7.2% 11.6% 9.8%
12 month 8.0% 8.5% 11.3%
24 month 5.4% 9.8%
36 month 6.5% 5.7%
48 month 5.2% 4.6%
60 month 6.0% 3.9%
1
Burch colposuspension and Fascial Sling groups
2
Retropubic and Transobturator Mid-urethral Sling groups
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